Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
DYN
DYN
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
DYN News
Dyne Therapeutics Receives Orphan Drug Designation for z-basivarsen, ACHIEVE Trial Shows Sustained Improvement
Jan 20 2026
Globenewswire
Stocks to Consider Buying in 2026: Insights from Our Roundtable Experts, Including DoorDash and LVMH
Jan 16 2026
Barron's
Dyne Therapeutics Closes $402.5 Million Upsized Public Offering
Dec 11 2025
Globenewswire
Dyne Therapeutics Closes $402.5 Million Upsized Public Offering
Dec 11 2025
Newsfilter
Oppenheimer Upgrades Dyne Ahead of Avidity's Upcoming Trial Results
Dec 10 2025
SeekingAlpha
Dyne Therapeutics Announces $350 Million Public Offering Pricing
Dec 10 2025
Yahoo Finance
Dyne Therapeutics Prices Upsized Public Offering of 18.98M Shares, Raising $350M
Dec 10 2025
Globenewswire
Dyne Therapeutics Prices Upsized Public Offering of 18.98 Million Shares, Raising $350 Million
Dec 10 2025
Newsfilter
Dyne Therapeutics Sets Price for Increased Public Offering of 18.98 Million Shares
Dec 10 2025
NASDAQ.COM
Reasons Behind the Decline of Dyne Therapeutics Stock on Tuesday
Dec 09 2025
NASDAQ.COM
Dyne Succeeds in Duchenne Trial; Sets Sights on Myotonic Dystrophy Goals
Dec 09 2025
NASDAQ.COM
Dyne Therapeutics Launches $300 Million Underwritten Public Offering
Dec 08 2025
Globenewswire
Dyne Therapeutics Launches $300 Million Underwritten Public Offering
Dec 08 2025
Newsfilter
Dyne's Duchenne Treatment Demonstrates Significant Muscle and Function Enhancements
Dec 08 2025
Benzinga
Reasons Behind the Surge in Dyne Therapeutics Stock Today
Dec 08 2025
NASDAQ.COM
Major Stocks on the Rise Monday: Paramount Skydance, Wave Life Sciences, Ocular Therapeutix, Carvana, and More
Dec 08 2025
Benzinga
Show More News
